HR for Biotech and Life Sciences Companies in Ontario: A Practical Employer Guide

Table of Contents

1. Ontario’s Life Sciences Landscape
2. The Unique HR Challenges in Biotech and Pharma
3. Workforce Types in Life Sciences
4. IP Protection Without Non-Competes
5. Health Canada Compliance and HR
6. Equity Compensation: Stock Options, RSUs, and the ESA
7. International Talent and Work Permits
8. Pay Transparency for Specialized Roles
9. OHSA in Laboratory and Research Environments
10. HR Support Models for Life Sciences Companies
11. Frequently Asked Questions

---

Ontario’s Life Sciences Landscape

Ontario’s life sciences sector is Canada’s largest, contributing over $42 billion to the provincial economy and employing more than 65,000 people as of 2024, according to Life Sciences Ontario. The sector is geographically concentrated but functionally diverse:

Sub-sector	Key Ontario Clusters	Typical Employer Size
Pharmaceutical manufacturing	Toronto, Mississauga, Brampton	200–2,000+ employees
Biotech R&D	MaRS Discovery District, University of Waterloo corridor, McMaster Innovation Park	10–200 employees
Medical devices	Toronto, Kitchener-Waterloo, Ottawa	25–500 employees
Contract research organizations (CROs)	Toronto, Mississauga, Hamilton	50–500 employees
Digital health / MedTech	MaRS, Waterloo Region	10–150 employees

Most Ontario biotech companies fall in the 15–150 employee range — past early research but not yet resourced for a full internal HR function. This is the stage where underdeveloped HR creates the most acute risk: rapid hiring, equity compensation, international talent, and regulatory compliance demands arrive simultaneously before any HR infrastructure is in place.

The Unique HR Challenges in Biotech and Pharma

HR Challenge	Why It Matters in Life Sciences	Ontario Compliance Risk
IP protection without non-competes	Researchers frequently leave for competitors or to start spinoff companies; IP created on the job is often the company’s core asset	Non-compete clauses are void for non-executives under the Working for Workers Act 2021 — relying on them is ineffective and does not create actual protection
GCP/GMP compliance training documentation	Health Canada requires documented training records for staff involved in clinical trials and drug manufacturing	OHSA training documentation runs parallel — failure in either creates distinct regulatory exposure
Equity compensation disputes at termination	Stock options and RSUs are critical retention tools; disputes about unvested equity at termination are common	Common law notice period may extend through vesting dates — lost equity is a recoverable head of damages
International researcher talent	Many biotech researchers are international graduates or established scientists recruited from outside Canada	IRCC work permit compliance; EPFNA obligations; SIN expiry and implied status management
Specialized talent shortage	Demand for bioinformaticians, regulatory affairs specialists, and clinical trial managers consistently outpaces supply nationally	Pay Transparency Act 2026 requires salary range disclosure for 25+ employee companies — critical for competitive postings
Laboratory safety and OHSA	Research environments involve biological agents, chemical hazards, and specialized equipment	O.Reg. 851 Industrial Establishments; WHMIS 2015; biosafety obligations for Level 2+ containment facilities
Rapid headcount changes tied to funding cycles	Clinical trial results and funding milestones drive fast hiring — and sometimes equally fast reductions	Mass termination rules (50+ dismissals in 4 weeks); Waksdale termination clause risk for companies using boilerplate agreements

Workforce Types in Life Sciences

Role Type	Employment Status	Key HR Consideration
Research scientists and postdoctoral fellows	Employees (not contractors in most cases)	IP assignment agreement essential before Day 1; academic publishing rights should be explicitly negotiated
Clinical research coordinators (CRCs)	Employees	GCP training documentation; Health Canada site qualification records; trial-specific delegation logs
Regulatory affairs / quality assurance staff	Employees	GMP documentation obligations; credential verification; SOP training matrices required
Manufacturing technicians	Employees	OHSA Schedule compliance; WHMIS; shift work ESA rules (overtime, rest periods, holiday pay formula)
Medical science liaisons (MSLs)	Usually employees — occasionally contractors	Classification risk is high; commission/expense structure; outside salesperson ESA exemption generally does NOT apply to MSLs who are primarily office/field-based
CRO and CMO relationships	B2B contract — not employment	IP ownership in CRO agreements must be explicitly addressed; sponsor retains Health Canada regulatory responsibility

Postdoctoral Fellows: The Employee Classification Question

A frequently misunderstood situation in Ontario’s biotech sector involves postdoctoral fellows at university-affiliated spinoffs or companies funded through research grants. The legal test for employment under the ESA is not how the relationship is labelled — it is the substance of the working arrangement.

If a postdoc is directed by the company, uses company equipment, and produces outputs owned by the company, they are very likely employees under the ESA — regardless of whether their compensation flows through a fellowship stipend. Misclassifying postdocs as fellows when they are functioning as directed employees exposes the company to retroactive ESA claims for vacation pay, public holiday pay, and notice entitlements upon departure.

IP Protection Without Non-Competes

Ontario’s Working for Workers Act, 2021 renders non-compete clauses void and unenforceable for all employees except those classified as executives (C-suite with significant business decision-making authority). This creates a genuine IP challenge in biotech, where a departing researcher may leave with deep knowledge of a pre-clinical pipeline and join a competitor.

What remains enforceable and effective in Ontario:

Protective Mechanism	Enforceability in Ontario	What It Covers
IP assignment clause	Fully enforceable — not a non-compete	All IP created during employment belongs to the company, including improvements to prior inventions and work created using company resources
Confidentiality / NDA	Fully enforceable	Trade secrets, proprietary research data, clinical trial data, formulations, manufacturing processes, regulatory strategies
Narrow non-solicitation	Enforceable if narrowly drafted	Prevents poaching current colleagues or existing clients — not a blanket prohibition on working in the sector
Garden leave clause	Enforceable if tied to actual compensation during the leave period	Keeps the researcher on payroll (and therefore in active confidentiality obligations) during a defined transition period before joining a new employer
Non-compete for C-suite	Enforceable for executives only — must be reasonable in scope	Geographic area, duration, and scope of restricted activity must all be reasonable — no blanket industry restrictions

Best practice for IP assignment: The IP assignment agreement must be signed before Day 1 of employment — not on the first day or after. Agreements signed after employment begins without independent consideration (beyond continued employment) may not be enforceable. The agreement should cover inventions, discoveries, data, know-how, and any derivative work created using company resources — including work done off-hours and off-premises if it relates to the company’s business.

For more on the non-compete ban and protective alternatives, see the employment contracts Ontario guide.

Health Canada Compliance and HR

Biotech companies conducting clinical trials or manufacturing regulated products are subject to Health Canada’s Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) standards. These create distinct HR documentation requirements that run parallel to — not instead of — Ontario OHSA obligations.

GCP Compliance (Clinical Trials)

HR Documentation Obligation	GCP Requirement (ICH E6)	HRIS / Tracking Implication
Training records for all trial staff	GCP training must be documented in the Trial Master File (TMF) — typically required every 2 years	HRIS must track completion dates and expiry; automated reminders before re-certification deadlines
CVs for key personnel	Current CVs for investigators, coordinators, and all study staff in the TMF	HR document storage for current CVs; annual confirmation process required
Delegation logs	The Principal Investigator must formally delegate study tasks to qualified personnel in the delegation log	Role qualification tracking; changes require updated delegation log — not just a verbal reassignment
SOP training records	Personnel must be trained to the current version of all applicable SOPs before performing study activities	Training matrix linked to SOP version control; version-specific completion records

GMP Compliance (Manufacturing)

For pharmaceutical manufacturers, Health Canada’s Good Manufacturing Practices guidelines require:

• A documented training program for all personnel working in the manufacturing area
• Role-specific competency qualification records — not just attendance records
• Periodic re-training on updated procedures and SOPs
• Training records available for Health Canada inspection at any time

Important intersection: OHSA WHMIS training is a separate obligation from GMP training. Both must be satisfied — OHSA compliance does not satisfy GMP training requirements, and vice versa. Your HR and quality systems must track both independently.

Equity Compensation: Stock Options, RSUs, and the ESA

Equity compensation is standard in Ontario’s biotech sector. Understanding how it interacts with Ontario employment law is critical for limiting termination risk:

Equity Type	ESA Treatment	Termination Risk
Stock options	Options are not wages under the ESA while unvested — plan terms govern vesting and post-termination exercise windows	Courts award damages for unvested options if the reasonable notice period would have extended through a vesting event — the value of the lost options is a recoverable head of damages
RSUs	RSUs that vest and are paid as cash or shares constitute income; unvested RSUs at termination may generate damages claims	Termination timed within 6 months of a material cliff vesting creates significant litigation exposure
Phantom equity / profit interest	Phantom equity payments earned during the common law notice period may be wages	If the phantom equity would have been paid during the reasonable notice period, damages include that amount

Practical rule: Before terminating an employee who holds unvested equity — particularly within 6–12 months of a material vesting event — obtain employment law advice. Ontario courts have consistently held that common law reasonable notice extends through vesting periods, and the equity value lost during that period is compensable. This can be the largest single component of a wrongful dismissal damages claim for biotech employees.

Vacation pay on RSU payouts: When RSUs vest and are paid in cash, vacation pay (4%/6%) may accrue on those amounts depending on plan structure. This is a frequently missed obligation that warrants a review of your equity plan’s interaction with Ontario vacation pay requirements.

International Talent and Work Permits

Ontario’s biotech sector is heavily reliant on international research talent — from globally recruited scientists to Ontario-trained international students entering the workforce. Key HR obligations vary by work authorization type:

Work Authorization Type	Who It Applies To	Employer HR Obligation
Post-Graduation Work Permit (PGWP)	International students who graduated from a designated learning institution (DLI)	Verify permit validity before hire; track expiry date; plan for PR application or employer-sponsored permit before expiry
LMIA-based closed work permit	Candidates where no PGWP or open permit is available	Labour Market Impact Assessment from ESDC; prevailing wage compliance; benefits obligations where applicable
Global Skills Strategy / C11/C10 LMIA exemption	Specialized knowledge workers; intracompany transfers	Faster processing; employer registration with ESDC in some cases; specific conditions by category
Open work permit (spousal, bridging, IEC)	Spouses of certain permit holders; PR applicants in process	Employer not responsible for the permit itself; must still track expiry and implied status; ensure the open permit covers the intended work

Implied status: When a work permit expires and the employee applied for renewal before the expiry date, they may continue working under “implied status” while the renewal application is pending. If the original permit was employer-specific (closed), the employee may only work for the same employer under implied status. Allowing an employee to work after a permit expires without a timely renewal application — or at a different employer — creates immigration non-compliance exposure for both the employer and the employee.

Ontario’s Employment Protection for Foreign Nationals Act (EPFNA) applies to internationally recruited workers. It prohibits employers from charging recruitment fees, withholding documents, providing false job descriptions, or penalizing workers for asserting their rights — regardless of whether those workers hold valid Canadian immigration status.

Pay Transparency for Specialized Roles

Ontario’s Pay Transparency Act 2026 (which amended the ESA) requires employers with 25 or more employees to include a compensation range in all publicly advertised job postings. For specialized biotech roles — where market data is thin and total compensation often includes equity — this creates practical compliance challenges:

• What to include in the range: The base salary or hourly rate range. If the role includes equity, you may note that equity compensation is included in the package — you do not need to detail the equity in the posting itself.
• No Canadian experience requirement: Postings cannot require Canadian experience as a condition of consideration. For biotech companies where many candidates trained internationally, this directly affects how qualification requirements are written.
• AI disclosure in hiring: If your applicant tracking system uses any form of automated screening or scoring (even basic keyword filtering), you must disclose AI use in the posting. Most biotech companies at 25+ employees use ATS platforms that trigger this disclosure requirement.
• 45-day candidate notification: Employers must notify all candidates who applied for a position within 45 days of filling the role or determining it will not be filled. This applies to the posted role regardless of whether AI was used.

For a full breakdown of Pay Transparency Act 2026 obligations, see the pay transparency Ontario guide.

OHSA in Laboratory and Research Environments

Ontario’s Occupational Health and Safety Act applies fully to biotech and pharmaceutical workplaces. Several regulations are particularly relevant to life sciences environments:

Regulation	Applies To	Key Obligation
O.Reg. 851 — Industrial Establishments	Manufacturing, QC labs, scale-up facilities, any industrial process	Equipment safety, machine guarding, chemical storage, PPE requirements — comprehensive and detailed obligations
WHMIS 2015 (O.Reg. 860)	Any workplace with hazardous products (includes virtually all biotech labs)	Safety Data Sheet availability, container labelling, worker training for all hazardous materials handled
O.Reg. 67/93 — Health Care and Residential Facilities	CRO or clinical settings where patient specimens are collected or handled	Biohazard protocols; needlestick and sharps injury prevention; biohazardous waste disposal procedures
Canadian Biosafety Standard (Public Health Agency of Canada)	Level 2+ containment laboratories	Biosafety officer designation; risk group assessment; containment zone protocols — federal standard incorporated by reference in OHSA duty of care

JHSC requirement: Workplaces with 20 or more regularly employed workers must establish a Joint Health and Safety Committee (JHSC). For biotech companies at this size, the JHSC should include at least one worker representative with direct knowledge of laboratory hazards — a general JHSC without lab representation is an OHSA compliance gap.

AED mandate (June 1, 2026): Workplaces with 20 or more workers and operations lasting 3 or more months must have an Automated External Defibrillator (AED) on site and ensure workers trained in its use are present during operations. Most biotech research facilities at this threshold will be captured. The AED must be in a clearly marked, accessible location.

Bill 190 (2024) digital harassment: Ontario’s OHSA now explicitly covers digital and electronic forms of workplace harassment and violence, including threats made via email, messaging platforms, and social media. Biotech companies — often with distributed teams and external collaborator networks — should update their workplace harassment programs to explicitly address digital harassment channels.

HR Support Models for Life Sciences Companies

Company Stage	Employee Count	Recommended HR Model	Approximate Annual Cost
Pre-clinical / early research	1–15	Fractional HR (project-based or low-retainer)	$8,000–$25,000
IND filing / Phase 1	15–40	Fractional HR retainer (operational level)	$30,000–$60,000
Phase 2–3 / scale-up	40–100	Fractional HR retainer + in-house HR coordinator	$100,000–$155,000 combined
Commercial stage / NDS approval	100–300	In-house HR manager + fractional CHRO oversight	$160,000–$260,000 combined
Post-commercialization	300+	Full internal HR team	$350,000–$600,000+ annually

What Fractional HR Covers for Biotech (15–100 Employees)

For companies in the most common Ontario biotech employee range, a fractional HR engagement typically covers:

• Employment contract design — IP assignment, confidentiality, equity vesting provisions, and termination clauses that withstand Waksdale scrutiny
• OHSA compliance program setup and maintenance — JHSC when required, WHMIS training records, incident and injury reporting processes
• Work permit tracking and EPFNA compliance for international researchers
• GCP/GMP-adjacent HR documentation — ensuring HR records do not create gaps in regulatory audits, and training record systems are inspection-ready
• Performance management frameworks appropriate for research staff — output-based and milestone-driven rather than time-based observation
• Pay transparency compliance and compensation benchmarking for specialized roles in a thin Ontario market
• Managing workforce reductions when funding cycles or clinical results require rapid headcount changes — including mass termination compliance and severance calculation

To explore what fractional HR services look like for your stage, or to discuss Ontario-specific HR risks in your organization, contact HRX Connect for a confidential consultation.

Frequently Asked Questions

Are postdoctoral fellows considered employees under Ontario’s ESA?

If postdocs are directed by the company, use company resources, and produce work owned by the company, they are likely employees under the ESA regardless of how the relationship is labelled. Misclassifying postdocs as fellows or trainees when they are functioning as directed employees exposes the company to retroactive ESA claims — including vacation pay, public holiday pay, and notice entitlements on departure.

How can an Ontario biotech company protect IP without a non-compete?

Non-compete clauses are void for non-executives in Ontario under the Working for Workers Act 2021. Effective alternatives include: a robust IP assignment agreement signed before Day 1 (covering all inventions, data, and know-how), a confidentiality agreement covering trade secrets and proprietary research data, narrow non-solicitation clauses (specific colleagues or clients, not sector-wide restrictions), and garden leave provisions for senior researchers that keep them on payroll — and in their confidentiality obligations — during the transition period.

Are stock options wages under Ontario’s ESA?

Options are not wages while unvested under the ESA. However, if an employee is terminated without cause and common law reasonable notice would have extended through a vesting date, the value of the lost unvested equity is a recoverable head of damages in a wrongful dismissal claim. Terminating an employee close to a significant vesting cliff creates serious financial exposure and should always be reviewed with employment law counsel before proceeding.

What work permit compliance obligations do Ontario biotech employers have for international researchers?

Employers must verify work authorization before hire, track permit expiry dates (and calendar reminders for renewal), manage implied status situations (where a renewal application was filed before expiry), and comply with the Employment Protection for Foreign Nationals Act (EPFNA). Allowing an employee to work without valid authorization — or failing to stop work when a permit has truly lapsed — creates immigration compliance exposure for the employer and can trigger Ministry investigations.

Does Ontario’s Pay Transparency Act apply to biotech job postings with equity components?

Yes. For employers with 25 or more employees, all publicly advertised postings must include a compensation range. For roles with equity compensation, you disclose the base salary range and may note that the total package includes equity — you are not required to detail the equity structure in the posting itself. AI disclosure is also required if your ATS uses automated screening, which most platforms now do by default.